Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408935 | 0.92 | LMNA (0.44) | CTSSCTSLCTSKUSP30ALDH1A1 | |
| SCHEMBL6401314 | 0.91 | CTSS (0.42) | CTSSCTSLCTSKCA2ALDH1A1 | |
| SCHEMBL6405204 | 0.88 | CTSS (0.40) | CTSSCTSLCTSKALDH1A1UTS2R | |
| SCHEMBL6401358 | 0.80 | CTSS (0.45) | CTSSCTSLCTSKMMP13USP30 | |
| SCHEMBL6404630 | 0.72 | L3MBTL1 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL7258293 | 0.72 | L3MBTL1 (0.44) | ALDH1A1KMT2A | |
| SCHEMBL6403319 | 0.72 | USP30 (0.45) | CTSSCTSLCTSKUSP30ALDH1A1 | |
| SCHEMBL6402653 | 0.71 | CTSS (0.47) | CTSSCTSLCTSKCTSB | |
| SCHEMBL6401370 | 0.71 | L3MBTL1 (0.40) | ALDH1A1KMT2A | |
| SCHEMBL6402831 | 0.71 | OPRK1 (0.45) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900237-B2 | Sulfonamide compounds as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | Celera Corporation | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158231-A1 | Sulfonamide compounds as protease inhibitors | PRSS1, PRSS3, SPINT2 | CTSS 13/4885CTSL 22/4885CTSK 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.